DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYTOSAR-U

« Back to Dashboard

Clinical Trials for Cytosar-u

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00002833	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002835	Combination Chemotherapy in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.

Clinical Trial Conditions for Cytosar-u

Condition Name

Condition Name for Cytosar-u
Intervention	Trials
Leukemia	11
Acute Myeloid Leukemia	10
Lymphoma	6

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cytosar-u
Intervention	Trials
Leukemia	34
Leukemia, Myeloid	21
Leukemia, Myeloid, Acute	20

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cytosar-u

Trials by Country

Trials by Country for Cytosar-u
Location	Trials
United States	42
Italy	24
China	1
Iran, Islamic Republic of	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cytosar-u
Location	Trials
Texas	28
California	2
Washington	2
Ohio	2
Massachusetts	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cytosar-u

Clinical Trial Phase

Clinical Trial Phase for Cytosar-u
Clinical Trial Phase	Trials
Phase 3	3
Phase 2/Phase 3	3
Phase 2	21

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cytosar-u
Clinical Trial Phase	Trials
Not yet recruiting	17
Completed	14
Recruiting	13

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cytosar-u

Sponsor Name

Sponsor Name for Cytosar-u
Sponsor	Trials
M.D. Anderson Cancer Center	28
National Cancer Institute (NCI)	22
Amgen	2

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cytosar-u
Sponsor	Trials
Other	43
NIH	22
Industry	19

Export unavailable in trial.
Subscribe for complete access.